A clinical trial was recently initiated to test the safety and therapeutic efficiency of placental gp96-peptide complexes against non-small cell lung cancer and hepatocellular carcinoma (HCC) (No. ChiCTR2100052023). Here, HSP90B1 is linked to hepatocellular carcinoma.